Overview

In the seventh episode of Pri-Med’s weekly web series on COVID-19, faculty will start off a multi-episode spanning discussion on COVID-19 treatment by analyzing recent evidence of antiviral therapies. They will also review the current recommendations regarding their use in patients with COVID-19. Therapies to be discussed in this episode will include:

  • Convalescent Plasma
  • Camostat Mesilate
  • Lopinavir/Ritonavir
  • Hydroxychloroquine and Chloroquine
  • Remdesivir

Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 05/14/2020 and they are subject to change as new information is published.

Learning Objectives

  • Recognize that currently no drugs have been proven to be safe and effective for the treatment of COVID-19
  • Review the various antiviral therapies under investigation for the treatment of COVID-19
  • Describe the potential limitations of various antiviral therapies under investigation 
     

     

     

Faculty

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health
Portland, OR 

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
Executive Director, UC Irvine Program in Medical Education for the Latino Community
UC Irvine School of Medicine
Irvine, CA 

Disclosures

The following relevant financial relationships have been disclosed by faculty: 

Ty J. Gluckman, MD, FACC, FAHA

Has disclosed no relevant financial relationships. 

Charles Vega, MD, FAAFP

Has disclosed no relevant financial relationships. 

 

Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation Statement

Pri-Med Institute designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporter

Not Applicable

Education Partner

Not Applicable


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.